Cargando…

Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors

Besides lipids, inflammation, angiogenesis, coagulation and fibrinolysis play very important roles in coronary artery disease (CAD). We measured gene expression of the inflammatory markers interleukin (IL)-1β (IL1B) and interferon (IFN)-γ (IFNG), vascular endothelial growth factor-A (VEGF-A) (VEGFA)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hrovat, Katja, Rehberger Likozar, Andreja, Zupan, Janja, Šebeštjen, Miran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324258/ https://www.ncbi.nlm.nih.gov/pubmed/35877573 http://dx.doi.org/10.3390/jcdd9070211

Ejemplares similares

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
por: Levstek, Tina, et al.
Publicado: (2023)

Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels
por: Rehberger Likozar, Andreja, et al.
Publicado: (2022)

Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors
por: Likozar, Andreja Rehberger, et al.
Publicado: (2023)

The Influence of Treatment with PCSK9 Inhibitors and Variants in the CRP (rs1800947), TNFA (rs1800629), and IL6 (rs1800795) Genes on the Corresponding Inflammatory Markers in Patients with Very High Lipoprotein(a) Levels
por: Levstek, Tina, et al.
Publicado: (2022)

LPA Genotypes and Haplotypes Are Associated with Lipoprotein(a) Levels but Not Arterial Wall Properties in Stable Post-Coronary Event Patients with Very High Lipoprotein(a) Levels
por: Rehberger Likozar, Andreja, et al.
Publicado: (2021)

Influence of lipid-lowering drugs on inflammation: what is yet to be done?
por: Ugovšek, Sabina, et al.
Publicado: (2021)

Atherosclerotic Cardiovascular Disease: Risk Assessment, Prevention and Treatment Strategies
por: Jeras, Jernej, et al.
Publicado: (2022)

PCSK9 as an Atherothrombotic Risk Factor
por: Sotler, Tadeja, et al.
Publicado: (2023)

TNF-α Predicts Endothelial Function and Number of CD34(+) Cells after Stimulation with G-CSF in Patients with Advanced Heart Failure
por: Ugovšek, Sabina, et al.
Publicado: (2022)

Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall
por: Ugovšek, Sabina, et al.
Publicado: (2022)

Lipoprotein(a)—The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation
por: Ugovšek, Sabina, et al.
Publicado: (2021)

Standardization of Coagulation and Fibrinolysis Methods
por: Jespersen, Jörgen
Publicado: (2000)

Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
por: Li, Tingting, et al.
Publicado: (2021)

PCSK9 and triglyceride-rich lipoprotein metabolism
por: Druce, Irena, et al.
Publicado: (2015)

Coagulation and fibrinolysis after head injury
por: Homma, M, et al.
Publicado: (1998)

Inhibition of Fibrinolysis by Coagulation Factor XIII
por: Rijken, Dingeman C., et al.
Publicado: (2017)

Coagulation and Fibrinolysis in Kidney Graft Rejection
por: Stallone, Giovanni, et al.
Publicado: (2020)

Coagulation and Fibrinolysis in Obstructive Sleep Apnoea
por: Bikov, Andras, et al.
Publicado: (2021)

PCSK9 Inhibition: Does Lipoprotein Size Matter?
por: Si‐Tayeb, Karim, et al.
Publicado: (2015)

Lipoprotein(a) and PCSK9 inhibition: clinical evidence
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

Platelet function, coagulation and fibrinolysis in patients with previous coronary and cerebrovascular ischemic events
por: Barbosa, Carlos José Dornas Gonçalves, et al.
Publicado: (2019)

Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease
por: Xu, Rui-Xia, et al.
Publicado: (2014)

Platelets, coagulation and fibrinolysis in breast cancer progression
por: Lal, Inder, et al.
Publicado: (2013)

Breaking boundaries—coagulation and fibrinolysis at the neurovascular interface
por: Bardehle, Sophia, et al.
Publicado: (2015)

The In Vitro Effects of Pentamidine Isethionate on Coagulation and Fibrinolysis
por: Al-Horani, Rami A., et al.
Publicado: (2019)

Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer
por: Fang, Lianghua, et al.
Publicado: (2021)

PCSK9: The Nexus of Lipoprotein Metabolism and Inflammation in COVID-19
por: Goonewardena, Sascha N., et al.
Publicado: (2023)

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
por: Kosenko, Tanja, et al.
Publicado: (2013)

Coagulation and fibrinolysis during the infusion of Corynebacterium parvum in man.
por: Cederholm-Williams, S. A., et al.
Publicado: (1978)

The role of coagulation/fibrinolysis during Streptococcus pyogenes infection
por: Loof, Torsten G., et al.
Publicado: (2014)

Activation of Markers of Inflammation, Coagulation and Fibrinolysis in Musculoskeletal Trauma
por: Reikerås, Olav, et al.
Publicado: (2014)

Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency
por: Elbers, Laura P B, et al.
Publicado: (2018)

COVID-19: The crucial role of blood coagulation and fibrinolysis
por: Coccheri, Sergio
Publicado: (2020)

Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites
por: Thaler, Johannes, et al.
Publicado: (2021)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
por: Reyes-Soffer, Gissette, et al.
Publicado: (2017)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
por: Mohamed, Farzahna, et al.
Publicado: (2023)

Enhanced expression of genes involved in coagulation and fibrinolysis in murine arthritis
por: Salvi, Roberto, et al.
Publicado: (2000)

Coagulation and Fibrinolysis Index Profile in Patients with ANCA-Associated Vasculitis
por: Ma, Tian-Tian, et al.
Publicado: (2014)

Impact of Arterial Procedures on Coagulation and Fibrinolysis - A Pilot Study
por: Polok, Kamil Jurand, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dlk26sp77l2qp85stqp1snvmp5